Key facts
- The Li Ka Shing Foundation said it would fund 30 patient places for histotripsy kidney tumor trials in Hong Kong.
- CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital were named as trial sites.
- Histotripsy uses focused sound waves to break apart tumors without surgical incisions, according to the report.
The Li Ka Shing Foundation said on November 11, 2026 that Hong Kong would host clinical trials of a non-invasive treatment for kidney tumors, with the foundation funding places for 30 patients across three private hospitals.
The hospitals named are CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital. The treatment, histotripsy, uses focused sound waves to break apart tumors without surgical incisions.
The foundation described the program as the first clinical trials of the technique for kidney tumors in Asia. The report did not state when the trials would begin, how patients would be selected or what regulatory approvals were required.